Rallybio

crash fall stock shares market economy down red arrow
Biotech

Rallybio drops lead program as phase 2 data disappoint

Racing toward a $1.6 billion market, the biotech stopped work on RLYB212 in a rare maternal immune disorder in response to phase 2 data.
Nick Paul Taylor Apr 8, 2025 8:52am
calculator calculate budget

Rallybio reins in preclinical, Monopar pivots to radiopharma

May 9, 2024 10:13am
maternal-fetal diseases pregnancy

J&J funds Rallybio in risk-busting rare pregnancy disease pact

Apr 10, 2024 4:00pm
layoffs cut staff reduction workforce

Rallybio drops 45% of workforce to extend cash runway into 2026

Feb 6, 2024 9:45am
parasail Blue Lagoon parachute

Abbvie's president adds COO title—Chutes & Ladders

Jun 30, 2023 9:30am
rocketship new blast off start up business development break off acquisition split

Rallybio reassembles behind fetal blood disorder med 2.0

Mar 6, 2023 11:48am